All Star Analysts Portfolio highlights: Dell, Genentech, EMC Corporation, and General Electric.

CHICAGO -- Zacks.com just released its latest additions and deletions to its proprietary All Star Analyst portfolio. Members on this exclusive list include Dell (NASDAQ:DELL), Genentech, Inc. (NYSE:DNA), EMC Corporation (NYSE:EMC), and General Electric (NYSE:GE). View the entire list of stocks on the All Star Analyst portfolio at http://at.zacks.com/?id=510

This exclusive portfolio represents all stocks with a Strong Buy rating from at least five analysts with a 5-Star All Star ranking. These are the brokerage analysts whose stock recommendations proved to be the most profitable for investors. Since July 2002, this portfolio has generated an annualized return of 12.92%, exceeding the S&P 500 by a margin of more than 50%. Here is a synopsis of why these stocks are in the All Star Analysts Portfolio:

Dell (NASDAQ:DELL) disappointed some analysts last month with fiscal second-quarter revenue that was below expectations and lackluster fiscal third quarter guidance. Nevertheless, the company reported a solid year-over-year improvement in earnings per share and remains a favorite with the All Star analysts. Excluding items, the company posted earnings of 38 cents per share, compared to 31 cents a year earlier. The result also matched the consensus. Revenues advanced 15% to $13.4 billion. Dell's CEO stated that its growth in the second quarter was characterized by share increases in every region.

Genentech, Inc. (NYSE:DNA) reported positive analysis earlier this week for its Herceptin treatment for women with HER2-positive metastatic breast cancer. According to a fourth Phase III study, Herceptin plus chemotherapy displayed a significant reduction in the risk of disease recurrence in women with early-stage HER2-positive breast cancer. "Based on the strength of the data from the two U.S. adjuvant studies presented at this year's American Society of Clinical Oncology (ASCO) meeting, we continue to anticipate filing a supplemental Biologics License Application (sBLA) for Herceptin in the adjuvant setting based on data from the U.S. studies in the first quarter of 2006," said Susan Desmond-Hellmann, M.D., M.P.H., Genentech president, product development. Genentech is an innovative company and remains one of the All Stars favorite picks in biotechnology.

EMC Corporation (NYSE:EMC) extended its storage software revenue lead for the 7th straight quarter, according to a recent report from IDC. In the second quarter, EMC had 30.6% revenue share, which increased its storage software lead to more than 10 share points and growing revenue nearly twice as fast as the closest competitor on a year-over-year basis. In its second quarter report from July, EMC generated earnings per share of 12 cents on total consolidated revenues of $2.34 billion. The earnings result matched the consensus and topped last year's eight cents. Revenue jumped 19%. EMC said the quarter's growth was driven by its market-leading mid-tier storage systems, increasingly popular virtual infrastructure software from its VMware subsidiary, and an expanding services business.

General Electric (NYSE:GE) recently announced that its third quarter and full year 2005 earnings forecast remains on track, despite the impact of Hurricane Katrina. The company's CEO stated that it has estimated the losses at GE Insurance Solutions from the storm and, despite the impact, remains confident in its expectations and therefore reaffirmed its earnings forecast for the quarter and year. GE's guidance for the quarter is earnings growth of 13% to 16%, and for the year at 12% to 14%. Such stability keeps this company on the All Stars' lists.

Discover all the current All Star Analyst rankings and top analyst recommendations at http://at.zacks.com/?id=511

About Zacks All Star Analyst Survey

To learn which brokerage analysts are the best in their field and what stocks they're recommending today, see the Zacks All Star Analyst survey. This exclusive survey, created with Fortune Magazine, reveals the "Best-of-Breed" brokerage analysts. They are the select group of winners from the universe of brokerage analysts - the ones who consistently beat the street - the few you should be following now. Visit the Zacks All Star Survey to find the best analysts and their top stock recommendations at http://at.zacks.com/?id=512

Top recommendations from All Star Analysts Highlighted in FREE Investment Newsletter

Each week, Zacks.com highlights investment insight and favorite recommendations from All Star Analysts and other leading investment experts. This is all part of our FREE e-mail newsletter, "Profit from the Pros." The only way to get these powerful insights is with a FREE subscription to the "Profit from the Pros" investment newsletter. Register for a free subscription at http://at.zacks.com/?id=513

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind Zacks is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. The goal is to unlock these pros' profitable insights for individual investors hard-pressed to find this valuable information in one source. A free subscription to "Profit from the Pros" weekly e-mail newsletter provides the best way to use these experts' insights for more profitable investing. Register for a free subscription to the Profit from the Pros newsletter at http://at.zacks.com/?id=514

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

(a) The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard and Poor's. The S&P 500 includes the reinvestment of all dividends, no transaction costs, and represents the gross returns before management fees.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.